Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations
Abstract Lung cancer incidence has increased worldwide over the past decades, with non‐small cell lung cancer (NSCLC) accounting for the vast majority (85%) of lung cancer specimens. It is estimated that lung cancer causes about 1.7 million global deaths per year worldwide. Multiple trials have been...
Main Authors: | Elisabeth Smolle, Katharina Leithner, Horst Olschewski |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-02-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13246 |
Similar Items
-
Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review
by: David John McMahon, et al.
Published: (2024-01-01) -
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
by: Fiorella Calabrese, et al.
Published: (2022-04-01) -
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
by: Arthur Geraud, et al.
Published: (2020-12-01) -
Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer
by: Maria Chiara Anania, et al.
Published: (2020-01-01) -
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
by: Miriam Grazia Ferrara, et al.
Published: (2020-05-01)